News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Teva Pharmaceutical Industries Limited (TEVA) Launches SYNCare™ Home Administration Support Program For Patients On SYNRIBO® (Omacetaxine Mepesuccinate) For Injection


9/3/2014 9:06:22 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

FRAZER, Pa.--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced the launch of SYNCareTM, a comprehensive program designed to support patients taking SYNRIBO® (omacetaxine mepesuccinate) for injection, for subcutaneous use, at home. Through the SYNCare program, patients will receive: home delivery of prepared, prescribed doses; all supplies needed for home administration; educational resources and injection training support; and a 24/7 toll-free hotline number. SYNRIBO® was recently approved by the U.S. Food and Drug Administration (FDA) for home administration. Adults with chronic or accelerated phase chronic myeloid leukemia (CML) who are no longer responding to, or who could not tolerate, two or more tyrosine kinase inhibitors (TKIs) now have the option of administering SYNRIBO® therapy at home.

Hey, check out all the research scientist jobs. Post your resume today!

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES